Robin Garner analyst

Currently out of the existing stock ratings of Robin Garner, 11 are a BUY (100%).

Robin Garner

Work Performance Price Targets & Ratings Chart

Analyst Robin Garner, has had 40% of price targets met with an average potential upside of 82.02%, reached in 146 days on average. Previously, Robin Garner worked at CRAIG HALLUM.

Robin Garner has documented 24 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on AVDL, Avadel Pharmaceuticals PLC at 12-Jan-2024.

Wall Street Analyst Robin Garner

Analyst best performing recommendations are on PCSA (PROCESSA PHARMACEUTICALS).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) on 5/27/2022. The price target of $15.5 was fulfilled within 348 days with a profit of $13 (520%), with a performance score of 14.94.

Average potential price target upside

LABP Landos Biopharma AVDL Avadel Pharmaceuticals PLC CUE Cue Biopharma FENC Fennec Pharmaceuticals PCSA Processa Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 19-Oct-2021

$20.42

$500

2 years 7 months 21 days ago
(01-Apr-2024)

0/2 (0%)

$-1.18 (-5.46%)

Hold Since 06-Jan-2023

$1

$14

3 years 10 months 16 days ago
(06-Jan-2023)

1/4 (25%)

$-3.05 (-75.31%)

713

Hold Since 12-Aug-2022

4 years 11 days ago
(11-Nov-2022)

0/2 (0%)

$53.4 (50.09%)

Buy Since 01-Mar-2021

$60

$90

4 years 3 months 10 days ago
(12-Aug-2022)

0/3 (0%)

$49.4 (466.04%)

Hold Since 01-Mar-2021

$70

$170

4 years 10 months 19 days ago
(03-Jan-2022)

0/2 (0%)

$17.8 (34.10%)

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?